NewAmsterdam Pharma Company NAMS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$212.73M-13.5% | -$203.82M+15.6% | -$221.07M-11.1% | -$165.72M+27.8% | -$187.36M+18.1% | ||
| $230K+53.3% | $220K+94.7% | $212K+183% | $176K+189% | $150K+173% | ||
| $62.21M+52.1% | $59.43M+76.8% | $54.82M+81.5% | $47.8M+73.2% | $40.91M+64.5% | ||
| -$141.92M-1.1% | -$147.78M+6.8% | -$144.39M+6.3% | -$124.12M+34.2% | -$140.43M+14.3% | ||
| $268K-11.6% | $246K-63.4% | $149K-77.8% | $182K-70.0% | $303K-24.6% | ||
| -$191.79M-222% | -$177.42M-182% | -$218.46M-32,409% | -$218.54M-35,962% | -$59.61M-14,728% | ||
| $34.07M-92.7% | $29.52M-95.5% | $472.45M+133% | $466.61M+130% | $467.85M+129% | ||
| -$297.13M— | -$293.18M— | $112.1M— | —— | —— | ||
| -$142.19M-1.0% | -$148.03M+7.0% | -$144.54M+6.6% | -$124.3M+34.3% | -$140.73M+14.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's cash flow data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.